201660-20-0

Upstream product

• 132646-27-6 4-<2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy>benzyl alcohol 

Downstream Products

• 848569-89-1 2-methyl-6-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyloxy}-4-propoxy-benzoic acid allyl ester 
• 1026229-31-1 Cyano-(3-cyano-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-1,1-dioxo-2,3-dihydro-1H-1λ⁶-benzo[d]isothiazol-3-yl)-acetic acid ethyl ester 
• 1026434-81-0 C₃₁H₂₇N₃O₈S 
• 1025801-29-9 2-Cyano-3-(2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzylsulfamoyl}-phenyl)-3-oxo-propionic acid ethyl ester 
• 1025923-56-1 2-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-1,1-dioxo-1,2-dihydro-1λ⁶-benzo[d]isothiazol-3-one 

Relevant academic research and scientific papers

ORGANIC COMPOUNDS

Compounds of the formula (I) provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the present invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.